The E3 ubiquitin ligase HUWE1 is required for KRAS-induced lung cancer.
Saved in:
| Title: | The E3 ubiquitin ligase HUWE1 is required for KRAS-induced lung cancer. |
|---|---|
| Authors: | Searle J; Cell Signalling Group, Cancer Research UK Manchester Institute, The University of Manchester, Manchester, UK. Joshua.searle@ucl.ac.uk.; Cancer Research UK Lung Cancer Centre of Excellence, The University of Manchester, Manchester, UK. Joshua.searle@ucl.ac.uk.; Lungs for Living Research Centre, UCL Respiratory, Division of Medicine, University College London (UCL), London, UK. Joshua.searle@ucl.ac.uk., Menotti M; Cell Signalling Group, Cancer Research UK Manchester Institute, The University of Manchester, Manchester, UK.; Cancer Research UK Lung Cancer Centre of Excellence, The University of Manchester, Manchester, UK., McDaid WJ; Cancer Research UK Lung Cancer Centre of Excellence, The University of Manchester, Manchester, UK.; Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK., Baker MJ; Cancer Research UK Lung Cancer Centre of Excellence, The University of Manchester, Manchester, UK.; Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK., Chaturvedi A; Cancer Research UK Lung Cancer Centre of Excellence, The University of Manchester, Manchester, UK.; The Christie NHS Foundation Trust, Manchester, UK., Ginn L; Cell Signalling Group, Cancer Research UK Manchester Institute, The University of Manchester, Manchester, UK.; Cancer Research UK Lung Cancer Centre of Excellence, The University of Manchester, Manchester, UK., Reed H; Cell Signalling Group, Cancer Research UK Manchester Institute, The University of Manchester, Manchester, UK.; Cancer Research UK Lung Cancer Centre of Excellence, The University of Manchester, Manchester, UK., Carter M; Cancer Research UK Lung Cancer Centre of Excellence, The University of Manchester, Manchester, UK.; The Christie NHS Foundation Trust, Manchester, UK., Blackhall F; Cancer Research UK Lung Cancer Centre of Excellence, The University of Manchester, Manchester, UK.; Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK.; The Christie NHS Foundation Trust, Manchester, UK., Lindsay CR; Cancer Research UK Lung Cancer Centre of Excellence, The University of Manchester, Manchester, UK.; Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK.; The Christie NHS Foundation Trust, Manchester, UK., Malliri A; Cell Signalling Group, Cancer Research UK Manchester Institute, The University of Manchester, Manchester, UK. angeliki.malliri@manchester.ac.uk.; Cancer Research UK Lung Cancer Centre of Excellence, The University of Manchester, Manchester, UK. angeliki.malliri@manchester.ac.uk.; Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK. angeliki.malliri@manchester.ac.uk. |
| Source: | Cell death & disease [Cell Death Dis] 2026 Apr 07; Vol. 17 (1). Date of Electronic Publication: 2026 Apr 07. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101524092 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-4889 (Electronic) NLM ISO Abbreviation: Cell Death Dis Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2041-4889 |
|---|---|
| DOI: | 10.1038/s41419-026-08672-7 |
